At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial
In Brief
A clinical study evaluating Pirfenidone and Standard of care for Covid19 and ARDS. Completed, enrolled 26 participants across 1 site.
Detailed Summary
A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC alone, in a population of COVID-19 induced severe ARDS. Patients will be randomized according to 1:1 ratio to one of the trial arms: Pirfenidone (intervention arm) or SoC (control arm).
Study Details
Timeline
Interventions
Treatment with Pirfenidone as mentioned in the experimental arm description.
Treatment with SoC as mentioned in the control arm description.